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To investigate molecular changes in multiple sclerosis (MS) normal-appearing cortical gray
matter (NAGM).
Methods
We performed a whole-genome gene expression microarray analysis of human brain autopsy
tissues from 64 MS NAGM samples and 42 control gray matter samples. We further examined
our cases by HLA genotyping and performed immunohistochemical and immunofluorescent
analysis of all human brain tissues.
Results
HLA-DRB1 is the transcript with highest expression in MS NAGMwith a bimodal distribution
among the examined cases. Genotyping revealed that every case with the MS-associated HLA-
DR15 haplotype also shows high HLA-DRB1 expression and also of the tightly linked HLA-
DRB5 allele. Quantitative immunohistochemical analysis confirmed the higher expression of
HLA-DRB1 in HLA-DRB1*15:01 cases at the protein level. Analysis of gray matter lesion size
revealed a significant increase of cortical lesion size in cases with high HLA-DRB1 expression.
Conclusions
Our data indicate that increasedHLA-DRB1 and -DRB5 expression in the brain of patients with
MS may be an important factor in how the HLA-DR15 haplotype contributes to MS patho-
mechanisms in the target organ.
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Multiple sclerosis (MS), the most common inflammatory
neurologic disease affecting young adults, is a chronic auto-
immune demyelinating disease of the CNS. If untreated, MS
leads to disability in a substantial proportion of patients. The
etiology of MS includes a complex genetic trait and several
environmental risk factors, which act in concert and con-
tribute to the main pathomechanisms including autoimmune
inflammation, de- and remyelination, axonal and neuronal
loss, astroglia activation, and metabolic changes.1 The
relative severity of these factors leads to the enormous
heterogeneity of MS with respect to clinical signs, course,
and response to treatment, but also pathologic composi-
tion of demyelinated lesions. The pathologic hallmark of
MS is the formation of focal areas of myelin loss in the
CNS. Besides the most commonly described white matter
lesions, extensive gray matter lesions can be found in the
MS cerebral cortex.2 In addition to the well-described
demyelinated gray matter lesions also diffuse gray matter
abnormalities in nonlesional normally myelinated areas have
been described.3–5 At the molecular level, little is known about
changes in normal-appearing cortical graymatter (NAGM) and
gray matter lesions in MS. In the last years, several tran-
scriptome studies ofMS brain tissues have been performed, and
a number of possible pathomechanisms could be identified such
as mitochondrial dysfunction, metabolic changes in astrocytes,
inflammation, and oxidative stress.3,6–8 A limitation of all these
studies is the low number of tissue samples and cases and
consequently the limited statistical power. The problem is
further accentuated by the heterogeneity ofMS, reflected by the
variable clinical course, different clinical symptoms and imaging
findings, and variability in pathology. As part of our published
studies,8–10 we collected a large number of well-characterized
human brain tissue samples from control and MS cases.
Here, we compared the expression pattern ofMSNAGMwith
control gray matter (GM) to understand if there are alter-
ations that may underlie or contribute to the formation of the
widespread cortical lesions as an important aspect of MS
pathology.
Methods
Tissue selection and characterization
MS and control tissue samples were provided by the UK MS
Tissue Bank (UK Multicentre Research Ethics Committee,
MREC/02/2/39), funded by the MS Society of Great Britain
and Northern Ireland registered charity 207495, or obtained
from the archives of the Institute of Neuropathology at the
University Medical Centre Göttingen. Additional control
samples were provided by the Pathology Department of the
University Hospital Basel. All cases were routinely screened
by a neuropathologist to confirm diagnosis of MS and to
exclude other confounding pathologies.11 In total, 104 gray
matter tissue blocks from 34 control cases and 101 NAGM
tissue blocks from 51 MS cases were used for this study
(table 1, further details in table e-1, links.lww.com/NXI/
A173). Criteria of in- and exclusion are described in figure
1A. Tissues were characterized further by staining for neuronal
nuclei (NeuN) (neurons), oligodendrocyte transcription factor
2 (oligodendrocytes), myelin oligodendrocyte glycoprotein
(MOG) (myelin), and CD68 (microglia) (figure 1B). Cryostat
sections (12 μm) from fresh-frozen tissue blocks were stained
as described before.8,10 Antibodies and detailed protocols are
described in table e-2, A and B (links.lww.com/NXI/A173).
Ethical approvals
Ethical approvals for all human tissues used were given
by the UK Multicentre Research Ethics Committee,
MREC/02/2/39 for the cases from London, by the Ethics
Committee of the University Hospital Basel for all cases
from Basel, and by the ethical review committee of the
University Medical Center Göttingen (#19/09/10) for all
cases from Göttingen.
RNA isolation and quality assessment
Total RNA from gray matter tissue was isolated using the
Zymo ZR RNA Microprep Kit (Zymo Research, Irvine, CA)
as described before.8 Degraded (RNA integrity index < 6)
and/or contaminated (260/280 nm ratio < 1.8; 230/280 nm
ratio < 1.8) samples were excluded from the study.
Microarray analysis and statistical analysis
From initially 151 NAGM and control gray matter samples,
35 were excluded due to the RNA integrity index being
below the threshold of 6, 8 samples were excluded due to
incongruence between the sex stated in the case reports and
Y-chromosome linked gene expression, and 2 samples were
excluded for being clear outliers in the principal component
analysis. In total, 42 tissue samples from 14 control and 64
tissue samples from 25 MS cases were used for the gene
expression analysis between NAGM and control GM (table
1 and table e-1, links.lww.com/NXI/A173). To minimize
experimental bias, microarray experiments were performed
together. All samples used for the gene expression study
originated from the UK MS Tissue Bank. Gene expression
profiling was performed using the Illumina complementary
DNA–mediated annealing, selection, extension, and liga-
tion assay according to the manufacturer’s protocol12 (Part
No. 15018210, Revision history D, April 2012, Illumina, San
Glossary
GM = control gray matter; HLA = human leukocyte antigen; MOG = myelin oligodendrocyte glycoprotein; MS = multiple
sclerosis; NAGM = normal-appearing cortical grey matter; NeuN = neuronal nuclei; OLIG2 = oligodendrocyte transcription
factor 2; SNP = single nucleotide polymorphism.
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Table 1 Patient data
Cases Sex Cause of death
p.m.














C01 M Myocardial infarction 8 70 Others 1
C02 M Cardiac failure and
pneumonia
14 65 Others 5
C04 F Acute pancreatitis 20 58 15:01 6
C07 M Rectal cancer and pneumonia 9 89 Others 1 1
C09 F Pneumonia 10 95 15:01 2 1
C10 F Esophagus cancer 9 85 Others 3
C11 F Bronchopneumonia and
cerebrovascular accident
9 93 Others 1 1
C13 M Cardiogenic shock 21 73 Others 4 2
C14 M Lung cancer, metastasized 26 77 Others 3 3
C15 M Myocardial infarction 18 64 Others 4 4
C17 F Congestive cardiac failure 24 84 Others 4 3
C18 M Carcinoma of the tongue 22 35 15:01 6 4
C20 F Ovarian cancer 13 60 Others 5 5
C21 M Cerebrovascular accident and
pneumonia
17 75 Others 4 9
C22 M Prostate cancer, metastasized 22 88 Others 1
C25 M Bladder cancer and
pneumonia
5 84 Others 3 4
C26 F Breast cancer, metastasized 12 87 Others 1 2
C27 M Renal failure and multiple
myeloma
24 75 Others 1 2
C28 F Cardiac failure 21 60 15:01 4
C29 M Pneumonia 20 60 Others 4
C30 M Pericardial tamponade 7 68 Others 4
C31 M Anaphylaxis 14 72 15:01 4
C32 F Pneumonia 16 71 15:01 4
C33 F Cardiac failure 12 83 Others 4
C37 F Pneumonia 14 72 Others 4
C38 F Pneumonia 3 88 Others 2
C39 M Acute cardiac death 10 69 15:01 6




22 77 Others 1 1
C47 M Cardiac failure and acute
erosive enteritis
15 53 Others 2
C48 M Asphyxia 11 61 15:01 2
Continued
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Table 1 Patient data (continued)
Cases Sex Cause of death
p.m.













C49 F Cardiac failure 16 77 Others 2
C50 M Cardiac failure 21 75 15:01 2
14 F
19 M
Ø = 15.0 Ø = 73.2 10 15:01
23 others
104 42
Cases Sex Cause of death
p.m.












M01 F Breast cancer and
pneumothorax
8 56 31 SPMS Others 7 5
M02 F Peritonitis 16 58 22 PPMS Others 5 2
M03 F NA 18 78 14 SPMS Others 3 1
M04 F Respiratory failure 21 42 18 SPMS 15:01 1
M05 F Sepsis 19 74 26 SPMS 15:01 1
M06 F Pneumonia 6 58 21 PPMS 15:01 6 10
M07 F Pulmonary embolus
and pneumonia
17 45 20 PPMS Others 2
M09 M Aspiration pneumonia 8 75 38 SPMS Others 1 1
M10 F Pneumonia 8 72 41 SPMS Others 1 2
M11 M Pneumonia 26 66 31 SPMS Others 1
M12 F NA 11 69 31 NA 15:01 3
M13 M Pneumonia 11 63 39 SPMS Others 2
M14 F Pneumonia 9 77 31 PPMS Others 4 3
M15 F MS 15 51 21 SPMS Others 2 2
M16 F Adenocarcinoma of
unknown primary
6 56 17 PRMS 15:01 1 1
M17 F Respiratory infection 10 49 19 SPMS Others 1
M18 F Pneumonia 13 66 30+ NA 15:01 3
M20 F Pneumonia 21 86 56 NA Others 2
M21 F Pneumonia 11 86 36 SPMS Others 1
M22 F MS 21 77 22 PPMS 15:01 1 1
M23 F Lung cancer,
metastasized
5 78 42 SPMS 15:01 4 5
M24 F Renal failure 31 49 18 SPMS Others 2 1
M26 F Bowel blockage and
heart failure
24 71 35 SPMS 15:01 1
M27 F Pneumonia 9 49 25 SPMS Others 1
M28 F Pneumonia 22 54 20 SPMS 15:01 3
M30 F Pneumonia 7 77 21 SPMS Others 2 1
M31 M Urinary tract infection
and MS
12 53 11 SPMS Others 1
Continued
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Diego, CA). BeadChips were scanned by the iScan Array
scanner (Illumina). All subsequent data analyses were
performed using the statistical software R (R core de-
velopment Team 2008; R version 3.5.0). Specifically, the
Bioconductor packages beadarray (version 2.30.0) and
illuminaHumanWGDASLv4.db (version 1.26.0) were used
for reading-in data files and for probe annotation (probes n
= 48,107). Between-array normalization was performed by
variance stabilizing transformation followed by a quantile
normalization using functions from the Bioconductor
package lumi (version 2.32.0). Only probes mapping to an
ENTREZ gene ID were retained. Probes with quality status
“bad” were removed. “Bad quality probes” are probe matches
repeat sequences, intergenic or intronic regions, or is unlikely
to provide specific signal for any transcript (according
to illuminaHumanWGDASLv4 annotation). Because the
resulting probes (n = 25,081) were still not unique, we selected
the probe with the highest variance across all samples,
neglecting sample values, which fall into the expression
range of negative control probes. This way, each gene is
Table 1 Patient data (continued)
Cases Sex Cause of death
p.m.











M32 F Pneumonia 18 39 21 PRMS 15:01 1 4
M33 M Pneumonia 19 38 17 PRMS Others 2 1
M34 M NA 9 92 54 PPMS 15:01 1 2
M36 M Pneumonia 16 44 16 SPMS 15:01 2
M40 M Respiratory failure 10 40 9 SPMS 15:01 3
M42 F MS 12 50 31 SPMS Others 2
M43 F Pneumonia 12 34 NA SPMS 15:01 1
M44 F Small bowel
obstruction
13 80 36 SPMS Others 2 1
M46 F Multiorgan failure and
sepsis
28 45 6 SPMS 15:01 2 3
M47 M Intestinal obstruction 12 37 27 PPMS Others 2
M48 F Pneumonia 24 78 47 SPMS Others 1 2
M51 F Pneumonia 12 59 27 PPMS Others 3 2
M52 M Pneumonia 24 45 25 SPMS 15:01 1
M53 F Sepsis and pneumonia 16 47 17 SPMS 15:01 4 4
M54 M MS 9 45 18 SPMS 15:01 1
M55 F MS 26 37 17 SPMS Others 2
M56 F Pneumonia 22 88 32 PPMS 15:01 1 2
M57 F COPD 17 58 16 PPMS Others 2 3
M58 F MS 7 80 37 SPMS 15:01 1
M59 F MS 13 42 11 SPMS 15:01 2
M60 F Respiratory failure 9 59 4 PPMS 15:01 2 3
M61 M Pancreatic cancer 10 61 26 SPMS 15:01 1 2
37 F
12 M







Abbreviations: COPD = chronic obstructive pulmonary disease; GM = control graymatter; NA = not available; NAGM = normal-appearing cortical graymatter;
p.m. time = postmortem time (hours); PPMS = primary progressive multiple sclerosis; PRMS = progressive-relapsing multiple sclerosis; SPMS = secondary
progressive multiple sclerosis.
The table shows the patient characterization and the use of the patient samples in the different experiments. A more detailed table is given in the
supplements (table e-1, links.lww.com/NXI/A173). HLA-DRB1*15:01 is highlighted in bold.
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represented by the probe, which contains most information
on potential expression differences, but ignores probes,
which appear artificially regulated due to false-negative
regulation introduced by single nucleotide polymorphisms
(SNPs). This strategy gave rise to 17,908 unique gene-level
probes.
Figure 1 Tissue processing for microarray and tissue characterization
(A) Flowchart to illustrate the process from the patient’s death to statistical analysis of the gene expression microarray. After dissection of the brain and
exclusion of confounding pathologies, the tissue blocks were sent to Basel, Switzerland. There, an immunohistochemical characterization was performed,
any tissue with bad preservation was excluded, and regions of interest were selected. After RNA isolation, the RIN was measured, and samples with RIN
smaller than 6 were excluded. Sample mix up was checked by wrong sex and by principal component analysis. (B) Representative images of control cortical
graymatter (case C30) andMSNAGM (caseMS08, asterisk delineates themeninges, I–VI indicate the 6 neuronal layers). NAGMwas defined as no loss ofMOG,
NeuN, or OLIG2 (inset, arrows) staining comparedwith control cases and no increase in CD68 comparedwith controls; i.e., occasional CD68+ staining intra- or
perivascular (inset, arrowheads) and nearly no CD68+ staining in the tissue. Scale bars: 250 μm; inset Olig2: 20 μm, inset CD68: 10 μm. IHC = immunohis-
tochemistry; MOG =myelin oligodendrocyte glycoprotein; NAGM = normal-appearing cortical graymatter; NeuN = neuronal nuclei; OLIG2 = oligodendrocyte
transcription factor 2; PCA = principal component analysis; RIN = RNA integrity index.
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HLA genotyping
Human leukocyte antigen (HLA) genotyping was performed
by Histogenetics (NY). Allelic variants were typed by se-
quencing at high resolution (3-field). Alleles bearing suffix
“G” in the A locus have identical sequences in exon 2 and exon
3 antigen recognition sites. Alleles bearing suffix “G” in the
DRB locus have identical sequences in exon 2 antigen rec-
ognition sites. Genotypes are shown in table e-3 (links.lww.
com/NXI/A173).
Immunofluorescence colocalization
Immunofluorescent colocalization was performed as de-
scribed before (table e-2A, links.lww.com/NXI/A173).8,10 As
tissue preservation is not optimal in fresh-frozen tissues, fur-
ther paraffin-embedded tissue blocks were stained for coloc-
alization. Paraffin-embedded tissue sections (2–3 μm) were
deparaffinized in xylene, rehydrated, and transferred to 3%
H2O2 in phosphate buffered saline (PBS) for 20 minutes at
4°C to block the endogenous peroxidase. After 3 washing
steps with PBS, the sections were incubated with blocking
buffer (10% fetal calf serum in PBS) for at least 20 minutes to
reduce unspecific antibody binding. Primary antibodies (table
e-2A) were diluted in blocking buffer and incubated overnight
at 4°C and then washed 3 times with PBS. Secondary anti-
bodies were incubated for 1–2 hours (table e-2A).
Histologic quantification
HLA-DRB1 protein expression was measured with Fiji (image
processing package including ImageJ)13 using the count objects
algorithm with the following parameters: lower threshold 0,
upper threshold 120 in green channel of red-green-blue color
space, size of objects 10 μm2–100 μm2, and circularity 0.25–1.00.
Cortical lesions were defined as areas with complete loss of anti-
MOG staining or areas with reduced myelin density clearly
demarcated from surrounding normal-appearing tissue. Only
cortical gray matter ranging from the white matter to the me-
ninges andwith all 6 neuronal layers visible in the adjacentNeuN
staining was used. NAGM and gray matter lesion areas were
outlined in Adobe Photoshop CS6 (version 13.0 x64; Adobe
Systems, CA), exported, and evaluated for area (in squared
millimeters) in ImageJ software (references 13 and 14, version
1.51s, Fiji distribution, NIH,Maryland). A schematic drawing is
shown in figure 4C.
Statistical analysis
All statistical analyses were performed using R.15 A p value
or false detection rate-adjusted p value smaller than 0.05 was
considered statistically significant. Expression data were ana-
lyzed using R and the Bioconductor package limma (version
3.36.5). Statistical analysis was performed using a linear model
with disease group and sex as factors. Because some patients
contributed multiple tissue samples (tissue blocks), we addi-
tionally distinguished these “technical” replicates from true bi-
ological replicates (patients) in the model to avoid a potential
inflation of significance by pseudoreplication. Specifically, the
duplicateCorrelation function of the limma package was used to
estimate a consensus correlation between technical replicates
and this value together with patient ID as a block factor entered
into the model fit function. To test the correlation between
HLA-DRB1 and HLA-DRA gene expression, a linear model
was used (figure 2J). To test the influence of the HLA-
DRB1*15:01 genotype and the HLA-DRB1 gene expression on
the demyelinated gray matter lesion area per total gray matter
area, p values were derived from a linear model weighted by
number of tissue blocks per patient (figure 4D). For all other
statistical tests, a 2-sided Welch t test was used.
Data availability
The gene expression data discussed in this publication have
been deposited in NCBI’s Gene Expression Omnibus,16 ac-
cession number GSE131282, ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE131282.
Results
HLA-DRB1 is significantly upregulated in MS
NAGM compared with control GM
We investigated the gene expression inMSNAGMand control
cases. All tissues were characterized histopathologically, and
tissues with signs of possible confounding pathologies were
excluded (figure 1A). As a result, only tissues without signs of
demyelination, neuronal degeneration, oligodendrocyte loss,
and without signs of inflammation such as microglia activation
and macrophage infiltration were included in the microarray
study (figure 1B). Differential gene expression analysis between
MS NAGM and control GM revealed HLA-DRB1 as the
most significant differentially regulated gene (figure 2A)
(fold-change [FC] = 4.62, adj. p value = 0.013). Besides
HLA-DRB1, we detected a trend toward upregulation for the
integrin subunit beta-1-binding protein 1 (ITGB1BP1), pro-
tein kinase cAMP-dependent type 1 regulatory subunit alpha
(PRKAR1A), long intergenic nonprotein coding RNA 115
(LINC00115), mitogen-activated protein kinase kinase kinase
7, also known as TGF1 (MAP3K7), and SLIT-ROBO Rho
GTPase activating protein 2 (SRGAP2) (figure 2A).
Further analysis of HLA-DRB1 expression showed that the
distribution of HLA-DRB1 expression was bimodal within
both the MS and the control group (figure 2B). Of special
interest is that the majority of individuals with high HLA-
DRB1 expression were in the MS group. As HLA genes often
show tight linkage disequilibrium patterns,17 we further in-
vestigated the expression of DRB5, DQA1, and DQB1, as
certain alleles of these genes were reported to form a tight
linkage group within the DR15 haplotype.18 The MS-
associated DR15 haplotype consists of 5 alleles, namely
DRA*01, DRB1*15:01, DRB5*01:01, DQA1*01:02, and
DQB1*06:02. Although not significantly differentially
expressed between MS and control cases (FC = 4.45, adj.
p value = 0.529), we also identified a bimodal distribution for
HLA-DRB5 (figure 2C). HLA-DQA1 and HLA-DQB1 ex-
pression levels were normally distributed (figure 2, D and E),
with HLA-DQB1 expression at the lower detection limit.
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Figure 2 Differential gene expression in MS NAGM vs control case cortical gray matter
(A) Volcano plot of the differential gene expression analysis between MS NAGM and control gray matter (GM) revealed HLA-DRB1 as the most significant
differentially regulated gene (FC = 4.62, adj. p value = 0.013, marked in red). Differentially expressed genes with an adjusted p value between 0.05 and 0.1 are
marked in black. This was the case for ITGB1BP1 (FC = 1.67, adj. p value = 0.065), PRKAR1A (FC = 1.93, adj. p value = 0.065), LINC00115 (FC = 1.5, adj. p value =
0.065), MAP3K7 (FC = 1.34, adj. p value = 0.067), and SRGAP2 (FC = 1.5, adj. p value = 0.067). Boxplots show the log2 gene expression of HLA-DRB1 (B), HLA-
DRB5 (C), andHLA-DQA1 (D) andHLA-DQB1 (E) betweenMSNAGMandGM. HLA-DRB1 is significantly differentially expressed betweenMSNAGMandGM (B).
Both, HLA-DRB1 (B) and HLA-DRB5 (C) show a bimodal expression pattern in MS and control tissue, whereas the expression of HLA-DQA1 (D) was normally
distributed within the sample groups, and HLA-DQB1 (E) was at the lower detection limit. (F) Boxplots show log2 of the HLA-DRB1 gene expression in all
tissue samples and in all cases used for the microarray analysis. All cases with the HLA-DRB1*15:01 genotype show a high HLA-DRB1 expression (red dots).
(G) HLA-DRB1 expression between samples from cases carrying the HLA-DRB1*15:01 or other HLA-DRB1 alleles. Boxplot shows that all HLA-DRB1*15:01
tissue samples belong to the HLA-DRB1 high expresser group. (H) HLA-DRB3, 4, and 5 expression of all samples. (I) Comparison of hetero- and homozygote
carriers of the HLA-DRB1*15:01 allele. (J) Correlation of HLA-DRB1 with HLA-DRA within the HLA-DRB1*15:01 positive samples. (H and I) p Values are derived
from a 2-sided Welch t test. (J) p Value is derived from a linear model.
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High cortical HLA-DRB1 expression is
associated with the HLA-DRB1*15:01 haplotype
The bimodal HLA-DRB1 expression pattern prompted us to
investigate whetherHLA-DRB1 expression in all tissue samples
from 1 individual shows this mode of expression. This analysis
revealed that single cases either expressed HLA-DRB1 at high
or low levels in bothMS and control cases (figure 2F). AsHLA-
DRB1*15:01 is strongest associated with MS risk19,20 and
HLA-DRB5 showed a similar expression distribution, we
genotyped all cases for HLA-DRB1, 3, 4, and 5 at a 3-field
resolution (table e-3, links.lww.com/NXI/A173). As expected,
we detected a trend toward higher frequency of the HLA-
DRB1*15:01 allele among theMS cases compared with control
cases (Fisher exact test, p = 0.083, OR = 4.5, 95% CI =
[0.8–50.2]).21 Gene expression analysis based on the HLA-
DRB1 genotype revealed that the bimodal distribution was
linked to the HLA-DRB1 genotype with individuals with the
HLA-DRB1*15:01 allele always showing high transcriptional
expression of HLA-DRB1 (n = 106 samples, figure 2, F andG).
In contrast to HLA-DRB1, which is expressed in every case,
only 11 MS and 1 control case turned out to carry the HLA-
DRB5 gene (table e-3). As expected, all individuals genotyped
positively for HLA-DRB5*01:01 allele were also positive for
HLA-DRB1*15:01 (table e-3). Compared with HLA-DRB3
and -DRB4 alleles in other DR haplotypes, HLA-DRB5*01:01
always showed a higher expression (p < 0.001, df = 79.33, for
DRB3, figure 2H; p < 0.001, df = 89.58 for DRB4, figure 2H).
Notably, there were no significant differences in HLA-DRB1
gene expression levels between hetero- and homozygotic car-
riers of the HLA-DRB1*15:01 allele (p = 0.379, df = 22.01,
figure 2I). Beside the cases carrying the HLA-DRB1*15:01
allele, 5 MS and 3 control cases also showed high HLA-DRB1
expression (figure 2F). Of these cases, one MS case was het-
erozygote for the HLA-DRB1*04:01 allele, and another case
was heterozygote for the HLA-DRB1*08:01:01G allele. Of
interest, both alleles have been associated with risk of MS.19,20
All 3 control cases were heterozygote for theHLA-DRB1*03:01
allele, also previously shown to be associated with MS19 (table
e-3, risk genes marked in bold). Of the other 3 MS cases
with high HLA-DRB1 expression, 2 did not carry a MS-
associated allele (HLA-DRB1*01:01:01, *01:01:01G, *01:03,
and *07:01:01G), and in 1 case, genotyping failed.
We did not detect any systematic differences between the
HLA-DRB1*15:01 cases compared with the other cases con-
cerning age at death, age at disease onset, and disease duration
(figure e-1, A–C, links.lww.com/NXI/A173). Also, we did
not detect any differences between the HLA-DRB1 high
expressing cases compared with the low expressing cases
concerning age at death, age at disease onset, and disease
duration (figure e-1, D–F).
HighHLA-DRB1expression correlateswithhigh
expression of HLA-DRA
Functional HLA-DR molecules are heterodimers of a DRA-
encoded alpha chain and a beta chain encoded by DRB1 or
DRB3,4,5, respectively. Therefore, we investigated whether
high HLA-DRB1 expression correlates with high HLA-DRA
gene expression in HLA-DRB1*15:01 carriers. Indeed, high
HLA-DRB1 gene expression correlated with high HLA-DRA
(r = 0.79, p < 0.001) gene expression in HLA-DRB1*15:01
cases, supporting the idea of a biologically functional upre-
gulation of MHCII in MS NAGM of HLA-DRB1*15:01 cases
(figure 2J).
HLA-DRB1 is expressed by microglia in human
cortical gray matter
To determine which cell types are expressing HLA-DRB1 in
NAGM, a confocal immunofluorescence colocalization anal-
ysis of fresh-frozen and paraffin-embedded human brain tis-
sues was performed (figure 3). We detected that HLA-DRB1
colocalized with microglia in MS NAGM and control GM
(figure 3A). No colocalization could be detected in astrocytes
(figure 3B), neurons (figure 3C), oligodendrocytes (figure
3D), or blood vessels (figure 3E).
HLA-DRB1 protein expression is elevated in
HLA-DRB1*15:01-positive cases
Quantitative immunohistochemical analysis was performed to
determine whether HLA-DRB1 gene and protein expression
are associated with each other (figure 4A). We detected
a higher protein expression in high vs low HLA-DRB1 gene
expressers (p = 0.052, df = 46.9, n = 49) (figure 4B) and
a trend toward higher expression in MS and control cases
carrying the HLA-DRB1*15:01 allele compared with non-
carriers (p = 0.097, df = 60.5, n = 74). HLA-DRB1 protein
expression varied considerably from case to case (figure 4B).
HLA-DRB1*15:01 genotype and increased
expression of HLA-DRB1 is associated with
increased cortical demyelination
We hypothesized that the HLA-DRB1*15:01 genotype and
the increased HLA-DRB1 gene- and protein expression might
be related to meningeal inflammation and cortical microglia
activation, previously described inMS,22 and hencemight also
correlate with increased levels of cortical demyelination.
We thus investigated all available tissue blocks from MS cases
with cortical lesions (table e-1, links.lww.com/NXI/A173)
and stained for MOG, delineated cerebral cortical area con-
taining all 6 layers (identified by NeuN) (figure 4C), and
quantified the fraction of demyelinated vs whole cortical area
(figure 4D). Areas of demyelination in MS cases carrying the
HLA-DRB1*15:01 allele, and respectively cases with a high
HLA-DRB1 gene expression, were significantly larger than in
HLA-DRB1*15:01-negative cases (p = 0.052, df = 23, n = 25)
and, respectively, cases with low HLA-DRB1 gene expression
(p = 0.014, df = 21, n = 23) (figure 4D).
HLA-DRB1*15:01 carrier status associates with
higher expression of 9 genes in cortical NAGM
in both MS and controls
We investigated the effect of the HLA-DRB1*15:01 allele by
analyzing the differential gene expression data after grouping
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the cases intoDRB1*15:01 positive or negative. We detected
9 genes to be differentially regulated. Most interestingly, our
data show an upregulation of interleukin 18 receptor 1
(IL18R1; FC = 1.73, adj. p value = 0.004) and leukocyte
immunoglobulin like receptor B1 (LILRB1; FC = 1.54, adj. p
value = 0.032). The highest fold change was detected for
long intergenic nonprotein coding RNA 01119
(LINC01119, FC = 4.35, adj. p value < 0.0001). We further
detected differentially expressed transcripts of protein
O-fucosyltransferase 2 (POFUT2; FC = 1.86, adj. p value
< 0.001), G protein subunit beta 5 (GNB5; FC = −2.20, adj.
p value = 0.003), epithelial stromal interaction 1 (EPSTI1;
FC = 1.50, adj. p value = 0.005), DExD/H-box helicase
60 (DDX60; FC = 1.25, adj. p value = 0.010),
N-acetylneuraminic acid phosphatase (NANP; FC = 1.47,
adj. p value = 0.012), and kinesin family member 25 (KIF25;
FC = −1.37, adj. p value = 0.049).
Discussion
Our results demonstrate that HLA-DRB1 is significantly
higher expressed in MS NAGM and shows a bimodal dis-
tribution with more MS cases showing a high expression
compared with control cases. Genotyping of the HLA locus
revealed an almost exclusive high expression of all HLA-
DRB1*15:01 allele carriers and of a few other MS-associated
risk alleles. Consistent with the gene expression analysis,
HLA-DRB1 protein expression is increased in HLA-
DRB1*15:01-positive cases in gray matter on microglia
based on immunofluorescence colocalization. The HLA-
DRB1*15:01 genotype and high HLA-DRB1 gene expres-
sion are associated with larger gray matter lesions in MS.
Furthermore, it is important to note that the second DR
allele, DRB5*01:01, which is tightly linked with DRB1*15:01
in the MS-associated DR haplotype is also expressed at
higher levels.
These findings hint at a link between the strongest genetic
risk factor for MS and an important pathologic hallmark,
namely demyelinated lesions in the cerebral cortex. We hy-
pothesize that the HLA-DRB1*15:01 genotype and the in-
creased HLA-DRB1 and-DRB5 gene expression together
with meningeal and parenchymal inflammation may lead
to larger demyelinated lesions. The correlation between
inflammation, cortical demyelination, and the HLA-
DRB1*15 allele has already been described in autopsy tissue
Figure 3 HLA-DRB1 colocalization in MS cortical gray matter
Immunofluorescent colocalization of
HLA-DRB1 with cellular markers for
resident cells of the cortical gray
matter. HLA-DRB1 colocalized with
CD68, a marker for microglia (A,
arrows). No colocalization with
astrocytes (B, GFAP, arrowhead),
neurons (C, NeuN, arrowhead), oli-
godendrocytes (D, OLIG2, arrow-
head), and blood vessels (E, CD34,
arrowhead) could be found. Scale
bar: 50 μm. GFAP = glial-fibrillary
acidic protein; NeuN = neuronal nu-
clei; OLIG2 = oligodendrocyte tran-
scription factor 2.
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by Yates et al.,23 who have detected more parenchymal,
perivascular, and meningeal T-cell inflammation and larger
motor cortical lesions in HLA-DRB1*15 carriers compared
with carriers of other alleles. Although MRI detection of
cortical gray matter lesion is improving, widespread subpial
demyelination is still difficult to detect.24 A recent MRI study
of 85 patients with MS did not reveal a statistically significant
difference between HLA-DRB1*15:01 carriers and non-
carriers; however, the authors point out the limited power
due to the small number of cases.25 Furthermore, meningeal
inflammation and follicle-like structures in the meninges
have been linked to microglia activity22 and larger subpial
cortical gray matter lesions.26 Regarding expression of the
2 DR15 alleles, higher messenger RNA expression of
Figure 4 HLA-DRB1 protein expression in MS and control cases and cortical gray matter lesion size in MS cases associate
with HLA-DRB1*15:01 allele
Representative image of immuno-
histochemical stainings for HLA-
DRB1 protein in a HLA-DRB1*15:01
positive (M6) and negative (M11) MS
case (A). Most HLA-DRB1*15:01 posi-
tive cases show an evenly distributed
staining of cells with microglia-like
morphology (arrow) throughout the
cerebral cortex (top panel), whereas
cases with other alleles may show
similar staining or no staining at all
(bottom panel, extreme case with no
staining). Scale bars: 500 μm, inset:
25 μm. Boxplots of the quantification
of the HLA-DRB1 immunohisto-
chemical staining (B) show MS and
control cases carrying the HLA-
DRB1*15:01 allele (left plot) or with
a high HLA-DRB1 gene expression
(right plot). Higher overall HLA-DRB1
protein expression was detected in
HLA-DRB1*15:01 positive cases and
high expressers compared with car-
riers of other alleles and low
expressers, respectively. Detection of
gray matter lesions in MS cases was
performed by immunohistochemical
staining for MOG (C shows repre-
sentative images of a 15:01 positive
[M28] and a negative [M3] MS case).
NAGM is demarcated by a black dot-
ted line and gray matter lesions by
a red dotted line; orange straight
lines demarcate the meninges. Scale
bar: 1,000 μm. Quantification of cor-
tical gray matter lesion size as frac-
tion of demyelinated vs total cortical
gray matter is shown (D). Both HLA-
DRB1*15:01 carriers (left plot) and
HLA-DRB1 high gene expressers
(right plot) show a larger mean lesion
size compared with carriers of other
alleles or low expressers, re-
spectively. (B and D) p Values are
derived from a 2-sided Welch t test.
MOG = myelin oligodendrocyte
glycoprotein.
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DRB5*01:01 compared with DRB1*15:01 in MS lesions and
normal-appearing white matter have already been observed
previously supporting our findings; however, much fewer
cases and neither gray matter nor the extent of de-
myelination had been studied.27
HLA class II molecules present processed peptides to CD4+
T lymphocytes. In MS, the strongest genetic association
maps to the HLA-DRB1 gene, whereas the association with
DRB5*01:01 has so far largely been ignored because the
SNPs, which have been used for determining DR types from
SNP typing, are not sufficiently tightly spaced in the HLA
region on chromosome 6 to allow assignment of the specific
HLA-DR3*, -4*, and -5* alleles.20 The HLA-DRB1*15:01
allele was reported to increase the risk for developing MS
about threefold.28 The higher HLA-DRB1 expression in the
cortical gray matter in HLA-DRB1*15:01 cases may there-
fore be involved in local activation of autoreactive CD4+
T cells. For CD4+ T-cell activation to occur, an interaction
between the T-cell receptor and major histocompatibility
complex (MHC) class II/peptide (pMHC) complexes is
required.29 The amount of antigen loaded on MHC class II
molecules of antigen-presenting cells and the level of MHC
class II expression determine the activation of CD4+ T-cell
activation, and higher pMHC ligand densities enhance this
process.30 Similar to the ectopic expression of HLA class II in
autoimmune thyroid disease,31 higher HLA-DRB1 expres-
sion by microglia in the brain may therefore affect the
pMHC concentration and consequently lead to an increased
probability of T-cell activation and brain inflammation. This
hypothesis is further supported by the finding that the level
of HLA-DR expression in transgenic mice is an important
prerequisite for developing spontaneous experimental au-
toimmune encephalomyelitis.32
Besides their expression levels, the nature of the peptide
repertoire that is presented by the 2 HLA-DR alleles in
the MS-associated DR15 haplotype, i.e., DRB1*15:01 and
DRB5*01:01,27 probably also plays an important role for the
activation of autoreactive T cells.33,34 Finally, autoreactive- and
virus-specific, brain-infiltrating CD4+ T cells may recognize
peptides in the context of both DR alleles of the DR15 haplo-
type, indicating that the expression of the 2 DRmolecules may
increase the likelihood of T-cell activation further.35,36
A bimodal expression pattern of HLA-DRB1 and -DRB5 has
been described in lymphoblastoid cell lines.37 The authors
analyzed expression quantitative trait loci in the tag of the
HLA-DRB1*15:01 allele associating with high HLA-DRB1,
DRB5, and DQB1 gene expression. They concluded that
a higher gene expression alone does not sufficiently explain
the MS-associated risk of the HLA-DRB1*15:01 allele. At
present, it is not clear which molecular pathomechanisms are
responsible for the high vs lower expression in some indi-
viduals, but differences in gene regulation, for instance by
different activation of the class II transactivator, is one
possibility.38
Regarding the potential functional involvement of the
DRB1*15:01 haplotype, the higher DRB1- and DRB5 ex-
pression in MS brains raises questions beyond peptide pre-
sentation to autoreactive T cells. The brain is considered an
immune privileged site, and besides shielding of the CNS
from the peripheral immune system via specialized barriers,
low MHC expression is considered an important aspect of
this CNS immune privilege.39 Aberrant and increased ex-
pression of HLA-DRB1 and -DRB5 may contribute to
breaking immune tolerance in this tissue that is exquisitely
vulnerable to damage and endowed with cells that are ter-
minally differentiated and not replaceable. The in-
terpretation of recent genome-wide association studies in
MS, which found almost exclusively immune system-related
genes, has been that MS develops from outside, i.e., the
peripheral immune system, in as opposed to starting by
damage within the CNS and then involving peripheral im-
mune cells, i.e., inside-out hypothesis.40 Our data, although
preliminary and not addressing functional aspects in human
brain tissue, might indicate that increased HLA-DR expres-
sion in the brain, if it preceded peripheral immune T-cell
activation, could play a role both within and later also out-
side the brain.
Regarding gene expression in cortical gray matter, several
studies have been performed with a relative small set of
NAGM tissue samples3,6,7 including ours.8 The present study
with a much larger number of cases and tissues did not show
the same gene expression alterations as the previous studies.
Possible reasons are the different gene expression platforms,
tissue preparation (fresh frozen vs paraffin embedded), the
statistical methods, and, most relevant, differences in the pa-
tient samples, which is a critical aspect in a heterogeneous
disease like MS.
The gene expression analysis further revealed 9 genes to be
differentially expressed in HLA-DRB1*15:01-positive vs
-negative samples. Among the detected genes, IL18R1 gene
and protein expression have previously been shown to be
elevated in MS in CSF and peripheral blood mononuclear
cells compared with controls.41 The highest fold change was
detected for LINC01119, a long intergenic non–protein-
coding RNA. Research on noncoding RNAs is rapidly
evolving, and somemembers have already been shown to play
a role in immune system regulation.42 We further detected
LILRB1, a receptor for class I MHC antigens expressed by
different leukocyte lineages that may downregulate monocyte
activation signals. EPSTI143 and DDX6044 have previously
been shown to be differentially regulated on interferon sig-
naling in HLA-B27-transgenic rats, an animal model de-
veloping spontaneous autoimmune-mediated multisystem
inflammatory disease.45 The other genes we detected were
POFUT2,46 GNB5,47 NANP,48 and KIF25.49 To the best of
our knowledge, these genes have not been described to date in
the context of MS or HLA-DRB as possibly linked to the
HLA-DRB1*15:01 allele. The power of this particular analysis
is however limited by the sample heterogeneity and needs
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further experimental investigation to evaluate the possible
impact of the detected differential expression.
In conclusion, our results demonstrate elevated DR ex-
pression in the cortical gray matter of a subset of patients
with MS positive for the HLA-DR15 haplotype and rarely
also other DR types. HLA-DRB1 expression by microglia
in the brain might play a role as vulnerability factor to
develop or sustain MS. Further studies on DR expression
in the brain, its causes, and consequences would therefore
be of great interest for a better understanding of MS
pathogenesis.
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